Impact of prostate volume on the active surveillance in prostate cancer

被引:0
|
作者
Beaujouan, Florent [1 ]
Bertherat, Walter [2 ]
Hammoudi, Zakaria [1 ]
Chicaud, Marie [1 ]
Descazeaud, Aurelien [1 ]
机构
[1] Univ Hosp Ctr Dupuytren, Dept Urol Surg & Androl, 16 rue Petiniaud-Beaupeyrat, F-87000 Limoges, France
[2] Perigueux Hosp Ctr, Dept Urol Surg & Androl, Perigueux, France
关键词
Prostatic neoplasms; active surveillance; prostate-specific antigen; prostatic hyperplasia; prognostic factors; FOLLOW-UP; ANTIGEN KINETICS; GUIDELINES; MANAGEMENT; DIAGNOSIS; OUTCOMES; PREDICT; UPDATE; BIOPSY; COHORT;
D O I
10.1177/20514158241303972
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the influence of the prostate volume (PVo) in the management of patients in active surveillance (AS) for prostate cancer. Materials and methods: A retrospective analysis of clinical, biological, histological and radiological data collected between 2010 and 2021 was performed for patients included in an AS protocol in a university hospital. The impact of initial PVo on the subsequent risk of exiting AS was evaluated. Results: In total, 109 patients were included in this analysis with a mean follow-up period of 52.74 +/- 31 months, 50% were out of AS by the end of the follow-up period. The risk of exiting the AS protocol was significantly associated to the PVo: patients with smaller PVo had an increased risk of exiting AS (p = 0.025). The maximal percentage of core invasion was the only initial predictive parameter for exiting the AS protocol on multivariate analysis of the global cohort (p = 0.010) and in the sub-group of patients having PVo <= 45 mL (p = 0.013). In the group having a PVo > 45 mL, no single initial parameter was significantly associated to a risk of exiting AS. Conclusion: Patients having small-sized prostate seemed to be at higher risk of exiting AS during follow-up.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Active surveillance of prostate cancer
    Hammerer, Peter
    Manka, Lukas
    ONKOLOGE, 2020, 26 (11): : 1069 - 1078
  • [2] Active surveillance for prostate cancer
    Dariane, C.
    PROGRES EN UROLOGIE, 2015, 25 (14): : 884 - 887
  • [3] Active Surveillance of Prostate Cancer
    Choyke, Peter L.
    Loeb, Stacy
    ONCOLOGY-NEW YORK, 2017, 31 (01): : 67 - 70
  • [4] Active surveillance for prostate cancer
    Romero-Otero, Javier
    Garcia-Gomez, Borja
    Duarte-Ojeda, Jose M.
    Rodriguez-Antolin, Alfredo
    Vilaseca, Antoni
    Carlsson, Sigrid V.
    Touijer, Karim A.
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (03) : 211 - 218
  • [5] Active surveillance in prostate cancer
    Erne, E.
    Kaufmann, S.
    Nikolaou, K.
    Stenzl, A.
    Bedke, J.
    UROLOGE, 2019, 58 (05): : 511 - 517
  • [6] Active surveillance of prostate cancer
    Ploussard, G.
    Hennequin, C.
    Rozet, F.
    CANCER RADIOTHERAPIE, 2017, 21 (6-7): : 437 - 441
  • [7] Active Surveillance for Prostate Cancer
    Thompson, Ian M.
    Klotz, Laurence
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (21): : 2411 - 2412
  • [8] Prostate cancer and active surveillance
    Abrahamsson, Per-Anders
    CONTROVERSIES IN THE TREATMENT OF PROSTATE CANCER, 2008, 41 : 1 - 6
  • [9] Active surveillance for prostate cancer
    Shill, Daniela K.
    Roobol, Monique J.
    Ehdaie, Behfar
    Vickers, Andrew J.
    Carlsson, Sigrid, V
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (06) : 2809 - 2819
  • [10] Active surveillance or prostate cancer
    Mottet, N.
    ONCOLOGIE, 2012, 14 (02) : 74 - 78